Dual-mode action of scalable, high-quality engineered stem cell-derived SIRPα-extracellular vesicles for treating acute liver failure
Seohyun Kim, Yoon Kyoung Kim, Seonghyun Kim, Yong‐Soon Choi, Inkyu Lee, Hyemin Joo, Jaehyun Kim, Minjeong Kwon, Seryoung Park, Min Kyoung Jo, Yoonjeong Choi, Theresa D’Souza, Jae Woong Jung, Elie Zakhem, Stephen Lenzini, Jiwan Woo, Hongyoon Choi, Jeongbin Park, Seung‐Yoon Park, Gi Beom Kim, Gi‐Hoon Nam, In‐San Kim
Abstract
Acute liver failure (ALF) is a life-threatening condition caused by rapid hepatocyte death and impaired liver regeneration. Here we show that extracellular vesicles engineered to express Signal Regulatory Protein Alpha (SIRP-EVs), produced via a scalable 3D bioreactor process with high yield and purity, exhibit significant therapeutic potential by targeting damaged cells and promoting tissue repair. SIRP-EVs block CD47, a crucial inhibitory signal on necroptotic cells, to enhance macrophage-mediated clearance of dying hepatocytes. They also deliver regenerative cargo from mesenchymal stem cells, reprogramming macrophages to support liver regeneration. In male animal models, SIRP-EVs significantly reduce liver injury markers and improve survival, demonstrating their dual-function therapeutic efficacy. By integrating the resolution of necroptosis with regenerative macrophage reprogramming, SIRP-EVs represent a promising platform for restoring liver function. These findings support the development of EV-based in vivo macrophage reprogramming therapies for ALF and other inflammation-driven diseases, paving the way for the clinical application of engineered EV therapeutics. Acute liver failure arises from rapid cell death and impaired liver regeneration. Here, the authors show that scalable, high-purity engineered extracellular vesicles derived from stem cells promote the clearance of dying hepatocytes and drive liver repair through in vivo macrophage reprogramming.